�鶹��Ѱ��Technology and Discovery News

�鶹��Ѱ��Boulder pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics

Daniel Corbin Leonard — Tue, 06 Jan 2026 21:18:56 +0000

�鶹��Ѱ��Boulder pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics Daniel Corbin … Tue, 01/06/2026 - 14:18

Heather Hansen

In an ongoing effort to bridge a pervasive investment gap in innovation funding, the �鶹��Ѱ�� has awarded pre-seed funding to Illumen Therapeutics, developing cancer treatments based on discoveries from startup co-founder Roy Parker’s lab at �鶹��Ѱ��Boulder.

Venture Partners at �鶹��Ѱ��Boulder recently created a pre-seed investment mechanism to help bridge the so-called “valley of death” between research and commercialization, where even high-potential start-ups can sometimes get lost, said Bryn Rees, senior associate vice chancellor for innovation and partnerships. “When somebody creates an innovation with broad potential to be translated out into a new venture, there is now funding to support the earliest stages of that new company,” said Rees. “This was a missing piece.”

The point of the pre-seed funding is “to bridge that gap between promise and follow-on investments,” he said. “We are building upon the brilliance of our faculty; they’re the ones who are saying, ‘I am trying to solve the hardest problems in the world’.”

What we do for university innovators

Venture Partners helps researchers, inventors and creators at �鶹��Ѱ��take their groundbreaking discoveries every step from intellectual property (IP) management to market launch.

Learn More

Pre-seed investments are made in promising companies translating �鶹��Ѱ��Boulder innovations through �鶹��Ѱ��Boulder License Equity Holdings (CUBLEH), a nonprofit entity separate from the university but run in partnership with it. Recognizing that a compelling startup could spin out from particular research or innovation is good for the university, researchers and society at-large, said Rees. “This is where the university really is stepping into opportunity and even responsibility to ensure that the products of its research are having that real-world impact,” he said. “This is why the pre-seed investment is so critical.”

The fund is intended to help energized, high-potential startups as they prepare for outside investment, a critical moment on their path to commercialization, said Hannah Nelson, associate director of licensing at Venture Partners. “Pre-seed funding gets placed in companies where we see momentum, an exciting commercial opportunity and a motivated founder, and I think that Illumen Therapeutics has shown all three of those things,” she said. “Another piece of what prioritizes companies for the pre-seed funding is that they’re already at that stage of development where we feel like this funding can unlock follow-on funds to get them to their next big inflection point.”

But what is "commercialization?"

The path to commercialization—also known as "research translation" or "tech transfer"—can be challenging, so Venture Partners unites industry partners, entrepreneurs and investors to help researchers, inventors and creators at the University of Colorado bring their groundbreaking discoveries into the marketplace.

Explore the Path to Commercialization

Arming the ‘guardian of the genome’

Illumen Therapeutics is focused on a cancer treatment ‘moonshot’ that pursues the long-sought ‘holy grail’ of drug development—but with an entirely new approach. That elusive goal revolves around a tumor suppressor gene called p53, dubbed the ‘guardian of the genome’ because it prevents damaged cells from multiplying, which blocks the formation and growth of tumors linked to a wide range of cancers.

“P53 is a key protein mutated in 85 to 95 percent of human cancers, and its loss allows cells to grow in an uncontrolled way,” explained Roy Parker, company co-founder, director of the BioFrontiers Institute and Cech-Leinwand Endowed Chair of �鶹��Ѱ��Boulder Biochemistry. “If you could restore p53 function, the hope is that would actually cause the tumors to either die or grow less.”

For several decades, popular strategies to target p53 have focused on blocking gene-inhibiting proteins. “There has been literally billions of dollars spent on this idea trying to target these inhibitors of p53,” said Parker, but all attempts have failed due to unexpected consequences like increased toxicity and a feedback loop that further suppresses p53. “The overall goal of increasing functional p53 is still a really important idea, and we just need ways to do that,” he said.

The leading-edge science behind Illumen Therapeutics, which emerged from the Parker Lab several years ago (including the work of postdoc fellow Siddharth Shukla), is based on a novel strategy to target PARN, an enzyme that affects p53. Inhibiting PARN to enhance functional p53 could potentially treat nearly half of all human tumors in aggressive cancers with limited therapeutic options like colorectal, triple-negative breast, pancreatic and others.“ That seems to be working, so that’s kind of proof of principle that if you could help p53, it might be really useful,” said Parker.

Parker envisions that any new therapeutic developed by Illumen will be used in combination with others to improve their effectiveness and could target subclasses of tumors that function differently than their broader tumor type. “A drug which even treats one subtype of cancer is still really important,” he said. “I’d be thrilled if we could reach that far.”

“We think it’s the key”

Despite the originality of the approach, the work was shelved until 2023, when Nelson connected with Bob Blomquist, a Boulder-based serial entrepreneur with biosciences expertise, who was looking for ideas with solid commercialization potential. One of the technologies Nelson thought might be a good fit was the PARN-p53 research from Parker’s lab.

Right away, Blomquist knew he wanted to learn more.

“When I met Roy and saw his data, it was like lights and sirens were going off,” he said. “That phenomenal discovery made by Roy’s lab may mean we can restore functional p53–that holy grail of cancer drug development. We think it’s the key.”

Blomquist, a trained geneticist, has spent decades of his business career working in oncology drug discovery, development and commercialization, and the more he dug into the technology, talking with experts, the more promising the innovation seemed. “I reached out to experts at MD Anderson [Cancer Center] and �鶹��Ѱ��Anschutz, and asked, ‘What do you think about this therapeutic strategy?’ And their eyes popped open, and their response was, ‘This could be the breakthrough we’ve been dreaming of’.”

Investor and Partnership Opportunities

Venture Partners seeks entrepreneurs to start new companies, connects investors with high-potential ventures and facilitates collaborations with companies seeking to invest in research or license technologies from the university.

Learn More

Blomquist co-founded Illumen in 2024 and credits both Venture Partners and Parker for helping build the strong team that’s now moving Illumen’s work forward. “The key role Venture Partners plays is so different than other institutions,” said Blomquist. “They really, truly work as a partner, helping to understand the science, how to connect with potential investors, and on and on. It’s a unique, strong and valuable partnership.”

The pre-seed funding is critical to helping Illumen reach its next inflection point, said Blomquist. “Having that investment got us started to de-risk the project, to show that this is a valid target and to duplicate the data, while we work on the rest of the financial raise,” he said

Rees also believes the investment is a solid one. “We have worked closely with the Parker Lab and with Bob for over a year, so we have a certain level of insight into the magnitude of the clinical impact, the strength of the underlying research and the compelling business case here in order to make the investment,” he said. “At the same time, that investment is absolutely necessary to hit those milestones and generate follow-on investor and partner interest.”

The passion behind Illumen is also personal for Blomquist, who lost his wife to triple-negative breast cancer in 2008. “This is why I get up in the morning, to make a difference in people’s lives. I can’t help my late wife, but what if we can help others? What if by developing a treatment with Roy’s technology we could turn treating cancer into a chronic illness? So that’s why I’m motivated to do something,” he said. “We’re all trying to make a difference.”

What Can We Do Together?

Disclose and Protect Your Innovation

Engage in Entrepreneurial Training Programs

Find a Mentor to Advance Your Innovation

Get Funding for Your Innovation

Find Partners and Opportunities for Your Innovation

Explore Investing in and Partnering with �鶹��Ѱ��Researchers

Explore Our Startups Portfolio

Explore Our Technology Portfolio

In an ongoing effort to bridge a pervasive investment gap in innovation funding, the �鶹��Ѱ�� has awarded pre-seed funding to Illumen Therapeutics, developing cancer treatments based on discoveries from startup co-founder Roy Parker’s lab at �鶹��Ѱ��Boulder.

Off

Traditional

White

NASA selects a �鶹��Ѱ��Boulder lab to build instruments for the moon

Daniel Corbin Leonard — Tue, 16 Dec 2025 19:15:38 +0000

NASA selects a �鶹��Ѱ��Boulder lab to build instruments for the moon Daniel Corbin … Tue, 12/16/2025 - 12:15

Denver7—NASA has selected a proposal from �鶹��Ѱ��Boulder researchers to design and build instruments that will be deployed by astronauts on the Moon. The instrument suite designed at the Laboratory for Atmospheric and Space Physics (LASP) will analyze lunar dust, which is abrasive like glass and sticks to all surfaces. Lunar dust can damage equipment and harm astronauts if inhaled.

Watch or Read this Story

Partnering Opportunities with �鶹��Ѱ��Technologies

Venture Partners manages a portfolio of over 1,000 technologies from university investigators and manages licensing partnerships with companies of all sizes—from startups to the Fortune 500—to bring these inventions to market. Discover how CU’s solutions can power your next breakthrough.

Explore Opportunities

Denver7—NASA has selected a proposal from �鶹��Ѱ��Boulder researchers to design and build instruments that will be deployed by astronauts on the Moon. The instrument suite designed at the Laboratory for Atmospheric and Space Physics (LASP) will analyze lunar dust, which is abrasive like glass and sticks to all surfaces. Lunar dust can damage equipment and harm astronauts if inhaled.

Off

Traditional

White

�鶹��Ѱ��Boulder lab creates bubble wrap-like window material that traps heat without blocking light

Daniel Corbin Leonard — Fri, 12 Dec 2025 20:18:14 +0000

�鶹��Ѱ��Boulder lab creates bubble wrap-like window material that traps heat without blocking light Daniel Corbin … Fri, 12/12/2025 - 13:18

A new, thin insulator has been designed to boost the energy efficiency of windows by blocking heat. Designed by a team from the �鶹��Ѱ��, this invisible window shield material has been dubbed Mesoporous Optically Clear Heat Insulator (MOCHI).

Partnering Opportunities with �鶹��Ѱ��Technologies

Explore Opportunities

Off

Traditional

White

Scientists use ultrasound to soften and treat cancer tumors without damaging healthy tissue

Daniel Corbin Leonard — Mon, 08 Dec 2025 20:23:40 +0000

Scientists use ultrasound to soften and treat cancer tumors without damaging healthy tissue Daniel Corbin … Mon, 12/08/2025 - 13:23

�鶹��Ѱ��Boulder Today—Cancer is one of the leading causes of death in the U.S., second only to heart disease. But a new cancer treatment method from �鶹��Ѱ��Boulder researchers uses sound waves to soften tumors and could be a potent tool against the disease.

Partnering Opportunities with �鶹��Ѱ��Technologies

Explore Opportunities

Off

Traditional

White

Agami Zero breaks through with magnetic hydrogen advance

Daniel Corbin Leonard — Wed, 03 Dec 2025 19:31:40 +0000

Agami Zero breaks through with magnetic hydrogen advance Daniel Corbin … Wed, 12/03/2025 - 12:31

Renewable And Sustainable Energy Institute—A startup team led by RASEI Fellow Oana Luca, called Agami Zero, has just secured seed funding after winning the 2025 �鶹��Ѱ��Lab Venture Challenge. Their winning idea? A new way to produce hydrogen fuel more efficiently, a key mechanism for decarbonizing our energy economy.

Off

Traditional

White

�鶹��Ѱ��Boulder leading $45M in ARPA-H grants for self-healing joints, wound care

Daniel Corbin Leonard — Tue, 02 Dec 2025 19:04:22 +0000

�鶹��Ѱ��Boulder leading $45M in ARPA-H grants for self-healing joints, wound care Daniel Corbin … Tue, 12/02/2025 - 12:04

�鶹��Ѱ��Boulder College of Engineering & Applied Science—In 2025, �鶹��Ѱ��Boulder celebrated its first awards from the Advanced Research Projects Agency for Health (ARPA-H). The new agency within the U.S. Department of Health and Human Services supports transformative health and biomedical breakthroughs. ARPA-H was founded in 2022 with a mission to fast-track “high-impact solutions to society’s most challenging health problems.”

Read the Full Story

Partnering Opportunities with �鶹��Ѱ��Technologies

Explore Opportunities

Off

Traditional

White

Researchers redefine hip arthroscopy with breakthrough surgical device

Daniel Corbin Leonard — Wed, 12 Nov 2025 23:17:28 +0000

Researchers redefine hip arthroscopy with breakthrough surgical device Daniel Corbin … Wed, 11/12/2025 - 16:17

�鶹��Ѱ��Boulder College of Engineering and Applied Science—The technology, published in the journal Arthroscopy Techniques, completely transforms arthroscopic procedures in the hip region, making them safer and more efficient than ever before.

Read the Full Story

Partnering Opportunities with �鶹��Ѱ��Technologies

Explore Opportunities

Off

Traditional

White

�鶹��Ѱ��Boulder delivers impactful research and creative work, despite federal funding uncertainty

Daniel Corbin Leonard — Fri, 31 Oct 2025 18:40:44 +0000

�鶹��Ѱ��Boulder delivers impactful research and creative work, despite federal funding uncertainty Daniel Corbin … Fri, 10/31/2025 - 12:40

�鶹��Ѱ�� researchers continued to deliver meaningful, positive outcomes in the university's public research mission through strong results in fiscal year 2024–25. Highlights of their work include big innovations in quantum technology, improving our understanding of space weather and enhancing environmental resiliency.

Read the Full Story

The Venture Partners Impact

FY 2023-24 was another tremendous year for innovation and entrepreneurship at the University of Colorado. University researchers, inventors and creators began working with Venture Partners at �鶹��Ѱ��Boulder to advance 144 breakthrough innovations, and 36 �鶹��Ѱ��startups were launched through Venture Partners based on university discoveries. These ventures spanned the breadth of CU's research expertise, with innovations in sustainability, biosciences, quantum science, optics and aerospace, to name a few.

Explore the Annual Report

Off

Traditional

White

$755,000 awarded to University of Colorado innovators to advance their discoveries

Daniel Corbin Leonard — Mon, 27 Oct 2025 22:18:03 +0000

$755,000 awarded to University of Colorado innovators to advance their discoveries Daniel Corbin … Mon, 10/27/2025 - 16:18

Eleven teams of University of Colorado faculty, researchers and graduate student innovators competed for a combined $755,000 in startup funding grants in this year’s Lab Venture Challenge (LVC). Judges from CU's entrepreneurial network heard Shark-Tank-style pitches across two nights, one for innovations in biosciences and another for physical sciences and engineering.

Interested in the 2026 LVC?

LVC supports �鶹��Ѱ��projects that address a commercial need, have a clear path to a compelling market and have strong scientific support.

Learn More

Through LVC, top innovators from �鶹��Ѱ��Boulder, Denver and Colorado Springs compete for grants to fund projects that address a commercial need, have a clear path to a compelling market and have strong scientific support. The LVC grants are funded by the Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industries Program, as well as Venture Partners at �鶹��Ѱ��Boulder and the Chancellor’s Innovation Fund. Six awards were granted this year, and the funding goes directly to �鶹��Ѱ��labs to further develop their innovations.

This culminating event for these groundbreaking teams showcased the university’s initiative to support innovators from discovery to economic success. LVC is run by Venture Partners at �鶹��Ѱ��Boulder, the university’s commercialization arm and central resource for researchers who wish to translate their work into impactful business and social ventures. As part of the LVC program, all the competitors worked with Venture Partners to protect their innovations and practice their funding pitches for business audiences. LVC awardees will continue to work and collaborate with Venture Partners on their path to commercialization.

“At this early stage, funding is essential, but can be a challenge to obtain,“ said Joshua Bennett, director of LVC and assistant director of licensing at Venture Partners. “All of these teams have promising innovations ready to launch new businesses. LVC is a unique opportunity for those innovators to receive that vital funding, and we’re proud to work with the State of Colorado to make it happen.”

To date, LVC has funded over 123 projects through 70 new deep-tech startup companies; collectively, these companies have raised over $349 million in follow-on financing.

Applications for the next LVC will open in July 2026.

This year’s LVC was additionally made possible by Berg Hill Greenleaf Ruscitti LLP, Holland & Hart LLC, Johnson & Johnson, Thermo Fisher Scientific and Paralex

Photo Credit: TJ Zirkman

2025 Physical Sciences Winners

$127,500—Magnetically Enhanced Electrolysis for H₂ Production

Magnetically Enhanced Electrolysis (MEE) improves hydrogen generation efficiency by enhancing bubble release and energy transfer. Adapted from space technology, MEE offers scalable, cost-effective clean hydrogen for transportation, industry and off-grid power. The team has formed a startup, Agami Zero, to bring their innovation to market.

Oana Luca (�鶹��Ѱ��Boulder Chemistry), PI
Ankur Gupta (�鶹��Ѱ��Boulder Chemical and Biological Engineering), Co-PI
Hunter Koltunski (Student: �鶹��Ѱ��Boulder Chemistry), Scientific Lead
Richard Noble (�鶹��Ѱ��Boulder Chemical and Biological Engineering), Scientific Advisor
Jafar Makrani, Co-Founder and CEO/CPO
Lyle Antieau III, Co-Founder and CTO/COO

$125,000—Low SWaP Frequency Comb for Quantum applications

Our Gen-III low-SWaP frequency comb, built on thin-film lithium niobate nanophotonics, delivers octave-spanning spectra with ultra-low power. Compact, scalable and robust, it enables deployable quantum clocks, sensors and communication systems beyond the lab. The team has formed a startup, Chi3 Optics, to bring their innovation to market.

Scott A. Diddams (�鶹��Ѱ��Boulder Electrical, Computer & Energy Engineering), PI
Tsung-Han Wu (Postdoc: �鶹��Ѱ��Boulder Electrical, Computer & Energy Engineering), Founder, CEO
Peter Chang, CTO
Nathan Brooks, Principal Scientist

$125,000—Novel Synergistic Catalysis for Clean Water and Fuel

A modular photo-thermo-catalysis device that rapidly activates a wide range of stubborn chemical bonds, enabling carbon-free fuel production at high reaction rates and the destruction of toxic PFAS in water, while reducing energy use and operating costs. The team has formed a startup, Synergia, to bring their innovation to market.

Longji Cui (�鶹��Ѱ��Boulder Paul M. Rady Mechanical Engineering), PI
Dishan Chooi (Student: �鶹��Ѱ��Boulder Paul M. Rady Mechanical Engineering), Technical Co-Lead
Sarang Gosavi (Student: �鶹��Ѱ��Boulder Paul M. Rady Mechanical Engineering), Technical Co-Lead
Yunxuan Zhu (Postdoc: �鶹��Ѱ��Boulder Paul M. Rady Mechanical Engineering), Director of R&D
Karen Crofton (�鶹��Ѱ��Boulder College of Engineering and Applied Science), Advisor

2025 Biosciences Winners

$127,500—Metabolite-Based Therapeutics for Obesity

Pythons exhibit dramatic metabolic plasticity with feeding, increasing organ size and activity by up to 40% after consuming large prey. From this biology, the team discovered a novel feeding-induced metabolite that was upregulated by 1,000-fold and acts as a natural appetite suppressant through modulating satiety. The team has formed a startup, Arkana Therapeutics, to bring their innovation to market.

Leslie Leinwand (�鶹��Ѱ��Boulder Molecular, Cellular & Developmental Biology), PI
Thomas Martin (Postdoc: �鶹��Ѱ��Boulder Molecular, Cellular & Developmental Biology), CSO
Jack Gugel, CEO
Yuxiao Tan (Postdoc: �鶹��Ѱ��Boulder Molecular, Cellular & Developmental Biology), Co-Founder

$125,000—Computationally Designed IL-18 binders to Treat Sepsis

Enabled by recent advances in AI-driven protein design, minibinders are being engineered to target IL-18, a key driver of sepsis. These compact, stable proteins penetrate tissues efficiently and can be precisely dosed to avoid prolonged immune suppression, offering a next-generation therapeutic for sepsis. The team has formed a startup, iMembrane Therapeutics, to bring their innovation to market.

Jingshi Shen (�鶹��Ѱ��Boulder Molecular, Cellular & Developmental Biology), PI
Suzhao Li (�鶹��Ѱ��Anschutz Medical Campus), President
Charles Dinarello (�鶹��Ѱ��Anschutz Medical Campus), Advisor

$125,000—Bioadhesive Patches That Seal Where Sutures Fail

DuraPatch provides rapid closure of cerebrospinal fluid (CSF) leaks during neurosurgery, eliminating the need for sutures. Engineered with high-resolution 3D printing and advanced biomaterials, DuraPatch strongly adheres to wet tissues to create a watertight seal while supporting and promoting healing. The team has founded a startup, Entangl3d, to bring their innovation to market.

Matt Davidson (�鶹��Ѱ��Boulder BioFrontiers Institute), CEO and Founder
Jason Burdick (�鶹��Ѱ��Boulder Chemical and Biological Engineering and BioFrontiers Institute) Co-Founder, PI
Peter Lennarson (�鶹��Ѱ��Anschutz Medical Campus), Advisor

Eleven teams of University of Colorado faculty, researchers and graduate student innovators competed for a combined $755,000 in startup funding grants in this year’s Lab Venture Challenge (LVC). Judges from CU's entrepreneurial network heard Shark-Tank-style pitches across two nights, one for innovations in biosciences and another for physical sciences and engineering.

Off

Traditional

White

�鶹��Ѱ��Boulder researchers advance miniature laser technology for biomedical imaging

Daniel Corbin Leonard — Tue, 14 Oct 2025 17:00:48 +0000

�鶹��Ѱ��Boulder researchers advance miniature laser technology for biomedical imaging Daniel Corbin … Tue, 10/14/2025 - 11:00

News-Medical.Net—�鶹��Ѱ�� researchers have developed a new miniature laser that could enable smaller, cheaper and more powerful biomedical imaging systems. The innovation advances chip-based frequency comb technology, paving the way for improved optical tools that could transform diagnostics and medical research.

Read the Full Article

Partnering Opportunities with �鶹��Ѱ��Technologies

Explore Opportunities

Off

Traditional

White

�鶹��Ѱ�����Technology and Discovery News

�鶹��Ѱ�����Boulder pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics

But what is "commercialization?"

Arming the ‘guardian of the genome’

“We think it’s the key”

What Can We Do Together?

Off

NASA selects a �鶹��Ѱ�����Boulder lab to build instruments for the moon

Partnering Opportunities with �鶹��Ѱ�����Technologies

Off

�鶹��Ѱ�����Boulder lab creates bubble wrap-like window material that traps heat without blocking light

Partnering Opportunities with �鶹��Ѱ�����Technologies

Off

Scientists use ultrasound to soften and treat cancer tumors without damaging healthy tissue

Partnering Opportunities with �鶹��Ѱ�����Technologies

Off

Agami Zero breaks through with magnetic hydrogen advance

Off

�鶹��Ѱ�����Boulder leading $45M in ARPA-H grants for self-healing joints, wound care

Partnering Opportunities with �鶹��Ѱ�����Technologies

Off

Researchers redefine hip arthroscopy with breakthrough surgical device

Partnering Opportunities with �鶹��Ѱ�����Technologies

Off

�鶹��Ѱ�����Boulder delivers impactful research and creative work, despite federal funding uncertainty

The Venture Partners Impact

Off

$755,000 awarded to University of Colorado innovators to advance their discoveries

2025 Physical Sciences Winners

$127,500—Magnetically Enhanced Electrolysis for H2 Production

$125,000—Low SWaP Frequency Comb for Quantum applications

$125,000—Novel Synergistic Catalysis for Clean Water and Fuel

2025 Biosciences Winners

$127,500—Metabolite-Based Therapeutics for Obesity

$125,000—Computationally Designed IL-18 binders to Treat Sepsis

$125,000—Bioadhesive Patches That Seal Where Sutures Fail

Off

�鶹��Ѱ�����Boulder researchers advance miniature laser technology for biomedical imaging

Partnering Opportunities with �鶹��Ѱ�����Technologies

Off

�鶹��Ѱ��Technology and Discovery News

�鶹��Ѱ��Boulder pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics

NASA selects a �鶹��Ѱ��Boulder lab to build instruments for the moon

Partnering Opportunities with �鶹��Ѱ��Technologies

�鶹��Ѱ��Boulder lab creates bubble wrap-like window material that traps heat without blocking light

Partnering Opportunities with �鶹��Ѱ��Technologies

Partnering Opportunities with �鶹��Ѱ��Technologies

�鶹��Ѱ��Boulder leading $45M in ARPA-H grants for self-healing joints, wound care

Partnering Opportunities with �鶹��Ѱ��Technologies

Partnering Opportunities with �鶹��Ѱ��Technologies

�鶹��Ѱ��Boulder delivers impactful research and creative work, despite federal funding uncertainty

$127,500—Magnetically Enhanced Electrolysis for H₂ Production

�鶹��Ѱ��Boulder researchers advance miniature laser technology for biomedical imaging

Partnering Opportunities with �鶹��Ѱ��Technologies